Journal issues > Issue 3, September 2015 > When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?

When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?

(Belg J Hematol 2015;6(3):88–90)

Highlights of a satellite symposium of Ariad held during the EHA congress 2015

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top